Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

US FDA agrees to accelerated review of Merck immunotherapy drug combination treatment for lung cancer

Wednesday, January 11, 2017 7:14
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Drugs giant Merck & Co. Inc. (NYSE:MRK) has gained a march on its rivals after US regulators agreed to an accelerated review of the use of one of its immunotherapy products with other drugs as a treatment for lung cancer.

The US Food & Drug Administration has accepted Merck’s application to review a combination of its immune system-boosting drug Keytruda with chemotherapy as an initial therapy for the largest cancer market.

The group said the FDA would decide by May 10 whether to approve the Keytruda combination treatment, with the drug already approved for the first-line treatment of lung cancer patients.

Merck presented good results from a mid-stage Phase II trial for its Keytruda-chemotherapy combination at conference in Denmark in October.

Immunotherapy is revolutionising some areas of cancer care, although providing it alone as a treatment only seems to work better than chemotherapy in previously untreated lung cancer patients.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/171479/us-fda-agrees-to-accelerated-review-of-merck-immunotherapy-drug-combination-treatment-for-lung-cancer-171479.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.